Genetic Background in Patients with Acute Myocardial Infarction

Shuichi AOKI, MD, Shuji MUKAE, MD, Seiji ITOH, MD, Ryuji SATO, MT, Kazuaki NISHIO, MD, Hiroaki UEDA, MD, Toshiki IWATA, MD, and Takashi KATAGIRI, MD

SUMMARY

The renin-angiotensin system is believed to play important roles in the development of acute myocardial infarction, and gene polymorphisms may also be involved. To investigate the genetic background in patients with acute myocardial infarction, we performed a case control study in a Japanese population.

The study included 150 patients with acute myocardial infarction and 150 healthy, age- and sex-matched controls. We examined polymorphisms of angiotensin II type 1 receptor (1166 A / C), type 2 receptor (3123 C / A), and bradykinin B2 receptor (-58 T / C) in these subjects.

The allelic frequencies of angiotensin II type 1 receptor C and angiotensin II type 2 receptor A were significantly higher in the acute myocardial infarction subjects than in the control subjects, and this tendency was more significant in the younger patients. The combined ratios of angiotensin II type 1 receptor C and type 2 receptor A alleles in patients under 64 years old were significantly higher than in their older counterparts. However, the total numbers of conventional coronary risk factors (hypertension, hypercholesterolemia, diabetes mellitus, and smoking) in individual subjects were not significantly different between younger and older patients.

These polymorphisms were found to be involved in the development of acute myocardial infarction, particularly in the younger patients, and it was concluded that the incidence of acute myocardial infarction might be reduced by management from the genotypes. (Jpn Heart J 2001; 42: 15-28)

Key words: Renin-angiotensin system, Polymorphism, Acute myocardial infarction, Coronary risk factor

HYPERTENSION, hypercholesterolemia, diabetes mellitus, and smoking have been identified as risk factors for coronary heart disease by many epidemiological studies. However, coronary heart disease is thought to result from the interaction of multiple environmental and genetic factors, one of which may be the renin-angiotensin system.1,2) It has been suggested that the components of the renin-
angiotensin system play a major role in the pathogenesis of a wide variety of cardiovascular diseases.3)

The major biologically active product of the renin-angiotensin system is angiotensin II, a peptide with multiple functions. In adult humans, the effects of angiotensin II are mainly mediated by the angiotensin II type 1 receptor, a G-protein-coupled receptor expressed by many cell types. On the other hand, human angiotensin II type 2 receptor genes have also recently been cloned and mapped to the X-chromosome.4,5) The expression of angiotensin II type 2 receptor is abundant in fetal tissues, but scanty in adult tissues.6,7) This receptor is also re-expressed in myocardial infarction, cardiac hypertrophy, vascular injury, and skin wounds.8-10) These findings suggest that the angiotensin II type 2 receptor is activated in various pathophysiological states and may play important roles in the pathogenesis of these states. Furthermore, angiotensin II type 2 receptor works cardio-protectively against type 1 receptor.11,12) Given the known physiological roles of these receptors, the angiotensin II type 1 and type 2 receptor genes are suspected as susceptibility factors for coronary heart disease.

Genetic variation has also been described in the components of the renin-angiotensin system.13,14) These genetic variations contribute to individual heterogeneity in the status of the renin-angiotensin system and thereby modify the relative role of the renin-angiotensin system in cardiovascular disease. Recently, investigators have described two genetic susceptibility factors for myocardial infarction that act synergistically on components of the renin-angiotensin system, i.e., the insertion / deletion (I / D) polymorphism of the ACE gene13) and the adenine (A) / cytosine (C) 1166 transversion of the angiotensin II type 1 receptor gene.14)

On the other hand, bradykinin in the kallikreins-kinin system, promotes all the major signs of inflammation such as hyperemia, leakage of plasma proteins, and pain.15-17) Bradykinin also exerts a cardioprotective effect on the myocardium. Kinins act mainly as local hormones by activating specific receptors known as B1 and B2 receptors, the latter of which mediates most of the inflammatory and cardiovascular effects.17-19) Human bradykinin receptor is a cell-surface, G-protein-coupled receptor of the seven-transmembrane-domained superfamily.15) The human B2 bradykinin receptor cDNA was cloned by Hess, et al.20) and subsequent studies of the genomic structure have shown the four polymorphisms.21-23) The bradykinin B2 receptor gene has been implicated as one of the candidate genes involved in the complex genetic underpinnings of essential hypertension and cardiovascular diseases. We already reported that the bradykinin B2 receptor −58 thymine (T) / cytosine (C) polymorphism was
GENE POLYMORPHISMS IN ACUTE MYOCARDIAL INFARCTION

Vo l  4 2
No 1

associated with the occurrence of essential hypertension in a Japanese population,24) and Braun supports our data by reporting that the luciferase promoter assay of −58C in the bradykinin B2 receptor was lower than that of −58T.23) Accordingly, we concluded that the transcriptional activity of the receptor promoter might be involved in the appearance of essential hypertension. However, there have been no other papers addressing associations between the bradykinin B2 receptor polymorphisms and diseases, so further study will be needed to clarify the role of this polymorphism.

In this study, we investigated how polymorphisms of the angiotensin II type 1 receptor, angiotensin II type 2 receptor, and bradykinin B2 receptor contribute to acute myocardial infarction (AMI) in a Japanese population. There have been many papers published on the ACE I / D polymorphism,13,25) as well as several others on the angiotensin II type 1 receptor A / C polymorphism in European and American populations with coronary heart diseases.14) In these studies, the physiological role of angiotensin II type 1 receptor implicates the angiotensin II type 1 gene as a candidate gene risk factor for myocardial infarction that may interact with the ACE I / D polymorphism. But other papers completely discount the relation between the angiotensin II type 1 receptor polymorphism and AMI.26,27) Hence, there is no established theory about the role of the angiotensin II type 1 receptor polymorphism in European and American populations. Furthermore, the mechanism of the angiotensin II type 2 receptor remains especially obscure, and few papers have described the angiotensin II type 2 receptor polymorphism. Several similar studies have been conducted on the ACE I / D polymorphism in Japanese populations,28,29) but few have described the angiotensin II type 1, type 2 receptors, or bradykinin B2 receptor polymorphisms in AMI subjects in Japan.30)

We investigated our hypothesis in a case control study comparing patients who survived myocardial infarction with appropriate controls recruited from a different Japanese population.

METHODS

Study population: Genetic polymorphisms were examined in 150 patients (102 men and 48 women) with AMI who underwent coronary angiography at Showa University Hospital, Tokyo, Japan in 1997-1999. AMI was diagnosed by clinical evidence of cardiac attack, electrocardiogram criteria, and serum cardiac enzyme concentrations. The clinical characteristics of the patients are shown in Table I. We defined conventional coronary risk factors as hypertension, hypercholesterolemia, diabetes mellitus, and
smoking, and the presence of these risk factors was determined from medical records diagnosed before admission due to AMI. The AMI was complicated with hypertension (46%), hypercholesterolemia (31%), diabetes mellitus (32%) and smoking (59%) in these patients. A smoking habit was defined as a daily intake of 10 or more cigarettes. Diagnosis of diabetes mellitus was performed according to the World Health Organization criteria.\textsuperscript{31)}

Normal healthy subjects ($n = 150$) on routine visits to medical centers in Tokyo were recruited as controls (102 men and 48 women) from the vital statistics of the Japanese Ministry of Welfare. Their status was confirmed by physical and laboratory examinations, including electrocardiography, and a history free from cardiovascular disease. All of their clinical data were within normal limits, including blood pressure, total cholesterol, and plasma glucose. All subjects gave informed consent to participate in the study, and the study was approved by the Showa University Ethics Committee. Blood samples were collected from the peripheral vein and stored in vacutainer tubes containing EDTA anticoagulant, and then genomic DNA was prepared from the white blood cells.

**Determination of Genotypes:** (1) Angiotensin II type 1 receptor 1166 adenine / cytosine polymorphism; The detection of the angiotensin II type 1 receptor 1166 A / C polymorphism was determined by polymerase chain reaction (PCR) and restriction isotyping using the restriction endonuclease Dde 1 and primers previously described by Doria, et al.\textsuperscript{32)} Alleles were visualized on 2% agarose gels stained with ethidium bromide. PCR was performed to amplify a fragment encompassing the A / C polymorphic site at the 1166 nucleotide position in the 3' untranslated region of the human angiotensin II type 1 receptor gene. The design of the primers was as follows: sense, 5’-ATAATGTAAGCTCATCCACC-3’; antisense, 5’-GAGAT-TGCATTTCCTGTCAGT-3’. The 30 $\mu$l reaction volume contained 100 ng genomic DNA, 10 pmol of each primer, 250 $\mu$mol / $l$ dNTP, 1.0 mmol / $l$
MgCl2, 50 mmol/l KCl, 10 mmol/l Tris-HCl at pH 8.3, and 0.5 units of Taq polymerase. Amplification was carried out using a Thermal Cycler (PERKIN ELMER 2400). Cycle conditions for PCR were heating for 5 min at 94°C, 40 cycles of 30 sec at 94°C, 45 sec at 55°C, and 45 sec at 72°C as the main reaction, followed by a final extension at 72°C for 10 min. After confirming that the PCR products showed exact amplification, they were digested with Dde I for 3 hours at 37°C. The digested products were visualized on 2% agarose gel by ethidium bromide staining.

(2) Angiotensin II type 2 receptor cytosine / adenine polymorphism; We designed the following primers: sense, 5'-GGATTCAAGTTTCTCTTTGAA-3'; antisense, 5' GCATAGGAGTATGATTTAATC-3'. PCR was performed under the same conditions used for the angiotensin II type 1 receptor gene polymorphism, with the exception of the annealing temperature, which was set at 53°C. After confirming DNA amplification, 10 µl of the PCR product was digested with 12 units of Alu I for 3 hours at 37°C, then electrophoresed on 2% agarose gel with ethidium bromide staining.

(3) Bradykinin B2 receptor −58 thymine / cytosine polymorphism; The primers for PCR amplification were sense, 5'- GCAGAGCTCAGCTGGAGGAG-3', located in the promoter, and antisense 5'-CCTCCTCGGAGCCCAGAAG-3', located in the promoter/exon 1. Primers were designed from the bradykinin B2 receptor gene reported by Kammerer, et al.22) The total reaction volume was 100 µl, in a mixture containing 1 µg of genomic DNA, 50 ng of each primer, 200 µmol of each dNTP, 1.5 mmol/l of MgCl2, and 0.5 units of Taq DNA polymerase. Cycle conditions for PCR were an initial step of 5 min at 94°C, followed by 30 cycles of 1 min at 94°C, 30s at 58°C, and 30s at 72°C, followed by a final extension of 5 min at 72°C. PCR products were subjected to single-strand conformation polymorphism (SSCP) electrophoresis. A 10 µl aliquot of the PCR product was diluted with 30µl formamide, denatured at 95°C for 10 min, and subjected to SSCP analysis in a 20% polyacrylamide (2 × TBE) gel. Electrophoresis was carried out in 2 × TBE buffer at 24°C at 180V for 20 hours, and the gels were then silver-stained. SSCP analysis of 300 unrelated Japanese subjects was performed in the same way. Several samples representative of each genotype detected by SSCP were sequenced by fluorescent cycle sequencing to confirm the thymine (T) or cytosine (C) at nucleotide position −58 upstream of the putative transcription start site.
**STATISTICAL ANALYSIS**

Differences in clinical characteristics between the subjects were examined by ANOVA for parametric data. Differences in the genotype and allelic frequencies between the groups were analyzed using the $\chi^2$ test, and Fisher's test was used for sets with small numbers. A probability of less than $p < 0.05$ was taken to be significant. In the multivariate regression analysis, the 3 polymorphisms and the presence of conventional coronary risk factors (hypertension, hypercholesterolemia, diabetes mellitus; absence = 0, presence = 1) were considered independent variables.

**RESULTS**

In samples obtained from 300 unrelated Japanese individuals, PCR-restriction fragment length polymorphism (PCR-RFLP) electrophoresis in a 2% agarose gel disclosed two sets of three genotypes for the angiotensin II type 1 and type 2 receptor gene polymorphisms, and PCR-SSCP electrophoresis in a 20% polyacrylamide gel disclosed one set of three genotypes for the bradykinin B2 receptor gene polymorphism. Figure 1 shows AA, CC, and AC genotypes of the angiotensin II type 1 receptor 1166 polymorphism, and CC, AA, and CA genotypes of the angiotensin II type 2 receptor 3123 polymorphism.

Figure 2 also shows genotypes for the bradykinin B2 receptor gene −58 thymine / cytosine polymorphism, and DNA sequencing showed a thymine (T) or cytosine (C) at nucleotide position −58 upstream of the

![Figure 1](image1.png)

**Figure 1.** Agarose gel electrophoresis of polymerase chain reaction products to determine Angiotensin II type 1 receptor A / C genotypes (digestion by Dde I) and Angiotensin II type 2 receptor C / A genotypes (digestion by Alu I). Angiotensin II type 1 receptor (1166 A / C), Angiotensin II type 2 receptor (3123 C/A).
putative transcription start site for the bradykinin B2 receptor gene polymorphism.

Table II shows the distributions of the genotypes and the allelic frequencies of the gene polymorphisms of angiotensin II type 1 receptor, angiotensin II type 2 receptor, and bradykinin B2 receptor in control subjects and AMI subjects. The genotypes and allelic frequencies were in Hardy-Weinberg equilibrium. In the distributions of the genotypes and the allelic frequencies of the angiotensin II type 1 receptor gene, significantly higher incidences of the AC genotype ($\chi^2 = 15.426, p = 0.0004$) and C
allele (odds ratio 3.22 (95% confidence interval 1.55 - 6.72, \( p = 0.001 \)) were seen in AMI subjects compared to controls.

Table II also shows the allelic frequencies of the angiotensin II type 2 receptor gene polymorphism. The angiotensin II type 2 receptor gene has been mapped to the X-chromosome, so here we only show the allelic frequencies. A significantly higher incidence of the A allele was seen in AMI subjects compared to controls, and the odds ratio was estimated as 2.43 (95% confidence interval 1.65 - 3.58, \( p = 0.0001 \)).

In marked contrast, the distributions of the genotypes and the allelic frequencies of the bradykinin B2 receptor gene were not significantly different between the AMI subjects and controls.

Incidentally, over the past decade, 916 AMI patients, aged an average of 64 years old were admitted to the coronary care unit at Showa University Hospital. Therefore, we divided the AMI subjects into two subgroups, those younger than 64 years old and those older, and we investigated the distributions of the genotypes and allelic frequencies of the genetic polymorphisms within these two groups.

Table III shows the distributions of the genotypes and allelic frequencies of the angiotensin II type 1 receptor, type 2 receptor, and bradykinin B2 receptor genes in AMI subjects less than 64 years old and over 64 years old. In the distributions of the genotypes and the allelic frequencies of the angiotensin II type 1 receptor gene polymorphism, significantly higher incidences of the AC genotype and C allele were seen in the younger group (allele, odds ratio 2.33 (95% confidence interval 1.03-5.28),

---

**Table III.** Distributions of Genotypes and Allelic Frequencies for Human Angiotensin II Type 1 Receptor, Type 2 Receptor and Bradykinin B2 Receptor Gene Polymorphisms in AMI Subjects Less than 64 Years Old and over 64 Years Old

<table>
<thead>
<tr>
<th>Genotype</th>
<th>64 &lt; AMI subjects (n = 78)</th>
<th>64 ( \geq ) AMI subjects (n = 72)</th>
<th>( \chi^2 ) test</th>
<th>Allele</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiotensin II type 1 receptor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>57 (73.1%)</td>
<td>63 (87.5%)</td>
<td>( \chi^2=4.868 )</td>
<td>0.87</td>
<td>0.13</td>
</tr>
<tr>
<td>AC</td>
<td>21 (26.9%)</td>
<td>9 (12.5%)</td>
<td>( \chi^2=0.027 )</td>
<td>0.94</td>
<td>0.06</td>
</tr>
<tr>
<td>CC</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Angiotensin II type 2 receptor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>0.6</td>
<td>0.74</td>
<td></td>
<td>0.49</td>
<td>0.51</td>
</tr>
<tr>
<td>A</td>
<td>0.4</td>
<td>0.26</td>
<td></td>
<td>0.54</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>Bradykinin B2 receptor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>17 (21.8%)</td>
<td>19 (24.4%)</td>
<td>( \chi^2=1.047 )</td>
<td>0.49</td>
<td>0.51</td>
</tr>
<tr>
<td>TC</td>
<td>42 (53.8%)</td>
<td>40 (55.6%)</td>
<td></td>
<td>0.54</td>
<td>0.46</td>
</tr>
<tr>
<td>CC</td>
<td>19 (24.4%)</td>
<td>13 (18.1%)</td>
<td></td>
<td>0.54</td>
<td>0.46</td>
</tr>
</tbody>
</table>

\( \chi^2 \) denotes the chi-square test statistic; \( p^* \) denotes the Bonferroni adjusted \( p \) value.
Furthermore, a significantly higher incidence of the A allele in the younger group was also seen in the allelic frequencies of the angiotensin II type 2 receptor gene (odds ratio 1.91 (95% confidence interval 1.17 - 3.12, \( p = 0.010 \))). On the contrary, there were no significant differences within these two groups in the distributions of the genotypes and allelic frequencies of the bradykinin B2 receptor gene, but a higher incidence of the T allele was seen in the overall population of AMI subjects (Table II) and in the older AMI group (Table III), while a higher incidence of the C allele was seen in the younger AMI group.

**Table IV.** Combination Ratios of Angiotensin II Type 1 Receptor C Allele and Angiotensin II Type 2 Receptor A Allele in AMI Subjects less than 64 Years Old and Over 64 Years Old

<table>
<thead>
<tr>
<th>Angiotensin II type 1 receptor C allele + type 2 receptor A allele</th>
<th>(+)</th>
<th>(-)</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>64 &lt; AMI subjects (n=78)</td>
<td>13</td>
<td>65</td>
<td>3.40 (95%CI 1.05-10.97)</td>
</tr>
<tr>
<td>(16.7%)</td>
<td>(83.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>64 ≥ AMI subjects (n=72)</td>
<td>4</td>
<td>68</td>
<td>( p^* = 0.032 )</td>
</tr>
<tr>
<td>(5.6%)</td>
<td>(94.4%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table V.** Multivariate Regression Analysis of Factors with Potential Effects on AMI

<table>
<thead>
<tr>
<th>Parameter</th>
<th>B</th>
<th>SE(B)</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin II type 1 receptor C allele</td>
<td>0.589</td>
<td>1.359</td>
<td>0.174</td>
</tr>
<tr>
<td>Angiotensin II type 2 receptor A allele</td>
<td>0.885</td>
<td>2.257</td>
<td>0.024</td>
</tr>
<tr>
<td>Bradykinin B2 receptor C allele</td>
<td>0.286</td>
<td>0.739</td>
<td>0.461</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.311</td>
<td>2.522</td>
<td>0.022</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>0.791</td>
<td>0.468</td>
<td>0.043</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.276</td>
<td>0.133</td>
<td>0.018</td>
</tr>
</tbody>
</table>

**Figure 3.** The total numbers of the conventional coronary risk factors in each AMI subject. Conventional coronary risk factors: hypercholesterolemia, diabetes mellitus and smoking.
Table IV shows the combined ratios of the polymorphic alleles of the angiotensin II type 1 receptor C and type 2 receptor A. Since the combined ratios of the polymorphic alleles were significantly higher in the AMI subjects younger than 64 years old than in their older counterparts, we know that the younger AMI subjects have more polymorphic alleles.

Furthermore, for multivariate logistic regression analysis, subjects \((n = 100)\) with hypertension or and hypercholesterolemia or and diabetes mellitus without AMI on routine visits to University Hospital were recruited in addition to the AMI subjects and controls. Multivariate logistic analysis (Table V) showed that only the angiotensin II type 2 receptor of these three genes was independently associated with the AMI, in contrast, the angiotensin II type 1 receptor and bradykinin B2 receptor were not independently associated with the AMI.

Figure 3 shows the total numbers of conventional coronary risk factors (i.e. hypertension, hypercholesterolemia, diabetes mellitus, smoking) in individual AMI subjects. There were a few more conventional coronary risk factors in the younger AMI subjects than in their older counterparts, but the differences in the total number of the conventional coronary risk factors between the groups were not significant.

**DISCUSSION**

In a large case-control study (ECTIM study), the ACE DD genotype was shown to be more frequent in patients with myocardial infarction than in control subjects.\(^{13}\) Many other studies have confirmed the association of the D allele with an increased risk of myocardial infarction,\(^{34-36}\) however, other studies did not detect any association between the D allele and risk of myocardial infarction.\(^{37-39}\) Differences in population selection or interactions with other genetic polymorphisms of the renin-angiotensin system such as the angiotensin II type 1 receptor or type 2 receptor polymorphisms may account for these discrepancies.

The physiological role of the angiotensin II type 1 and type 2 receptors suggest that these genes might be candidate genes for myocardial infarction, possibly in interaction with the ACE I / D polymorphism.

In addition, angiotensin II receptor antagonists have recently been applied clinically for hypertension and congestive heart failure. The pharmacological mechanism of angiotensin II receptor antagonists, namely, inhibition of the angiotensin II type 1 receptor and stimulation of the angiotensin II type 2 receptor,\(^{11,40}\) poses interesting questions about the angiotensin II receptor polymorphisms. Angiotensin II type 1 and type 2
receptors work controversially, and the angiotensin II type 2 receptor polymorphism may relate to the important function of angiotensin II-angiotensin II type 2 receptor that leads to the development of common diseases. However, since few papers have described the angiotensin II type 2 receptor and its precise mechanism, further study will be needed to clarify the role of angiotensin II type 2 receptor.

In this study, we have found evidence for heterogeneity in genotype distributions. Since there were significant differences in genotypes and allelic frequencies in the angiotensin II type 1 receptor A/C and angiotensin II type 2 receptor C/A polymorphisms between AMI and control subjects, we conjectured that the angiotensin II type 1 receptor 1166A/C polymorphism might interact with the angiotensin II type 2 receptor 3123C/A polymorphism to promote the occurrence of AMI, and the co-presence of additional polymorphisms compound this process. Furthermore, these tendencies were more significant in the younger group of AMI subjects.

The angiotensin II type 1 receptor 1166 A/C polymorphism is located at the 5' end of the 3' untranslated region and does not alter potential messenger (m)RNA polyadenylation or destabilization signals. However, this polymorphism might be a marker in linkage disequilibrium with an unidentified functional variant that could affect the regulation of the gene in response to angiotensin II. Studies in a rat model that overexpresses the angiotensin II type 1 receptor in the myocardium suggest that the overexpression of the angiotensin II type 1 receptor under physiological conditions causes no change in cardiovascular structure, but pressure and volume overload in the same model led to hypertrophic growth. These results indicate that the angiotensin II type 1 receptor polymorphism in itself does not cause cardiovascular disorders, but they also suggest that this polymorphism can contribute to a process started by other factors. One of these factors could be the activity of plasma renin and its uptake by certain tissues, leading to local activation of the renin-angiotensin system. Generally speaking, it seems that in the development and progression of cardiovascular disease, genetic variation in the renin-angiotensin system becomes especially important when combined with other risk factors.

On the other hand, the present study suggests that there was no significant relation between the bradykinin B2 receptor polymorphism and AMI. While the bradykinin B2 receptor polymorphism may not influence the pathogenesis of AMI as strongly as angiotensin II type 1 and type 2 receptor polymorphisms, this polymorphism should not be overlooked, particularly in younger patients. This confirms that the bradykinin B2
receptor polymorphism does not directly influence the occurrence of AMI, but we know that hypertension is an important coronary risk factor, and we already reported that the bradykinin B2 receptor –58T/C polymorphism was associated with the occurrence of essential hypertension, and the cardioprotective effect of ACE-inhibitor, an important effect for the inhibition of remodeling after acute myocardial infarction, is the inhibition of the degradation of bradykinin. Therefore, bradykinin B2 receptor polymorphism may influence the occurrence of AMI via hypertension, thereby influencing the pathogenesis of AMI indirectly.

Logistic analysis showed that the angiotensin II type 2 receptor of these three genes was independently associated with the AMI. In contrast, the angiotensin II type 1 receptor and bradykinin B2 receptor were not independently associated with the AMI, so we know that the influence of these gene polymorphisms to the pathogenesis of AMI was weaker than conventional coronary risk factors such as hypertension, hypercholesterolaemia, and diabetes mellitus. However, there has been no evidence until now that the polymorphisms of the angiotensin II type 1 receptor, type 2 receptor, and bradykinin B2 receptor are not related to hypertension, hypercholesterolaemia and diabetes mellitus, so it is difficult to decide whether the gene polymorphisms and conventional coronary risk factors are independent from each other. Therefore the influence of these gene polymorphisms on AMI may be multifactorial. Conventional coronary risk factors can directly or indirectly influence these polymorphisms, thereby altering the status of the renin-angiotensin system and the kallikreins-kinin system.

In conclusion, gene polymorphisms of the angiotensin II type 1 and type 2 receptors may promote the occurrence of AMI, and the co-presence of additional gene polymorphisms compound this process. These gene polymorphisms appear to be a new coronary risk factor, and they are probably associated with an increased responsiveness to angiotensin II. The occurrence of AMI might be reduced by management based on the genotypes.

REFERENCES
